Group To Press India Compulsory Licensing For Score Of Cancer Drugs
This article was originally published in PharmAsia News
Executive Summary
An Indian patient advocacy group says it plans to draw on support from other health care groups and seek a compulsory license for 20 cancer drugs. Most of the targeted drugs are made by major international drug makers. Cancer Patients Aids Association says it will try to convince the health ministry to invoke the compulsory licenses and is ready to take the matter to the Supreme Court. CPAA President Y. K. Sapru said it makes no sense to fight patent cases against individual drugs. A challenge to the Novartis patent for its leukemia drug Gleevec (imatinib mesylate) failed last year. (Click here for more